1.2 List of Figures
Figure 1: Women’s Health Drugs Market, 7MM, Epidemiology Patterns for Endometriosis, 2017-2024 19
Figure 2: Women’s Health Drugs Market, 7MM, Epidemiology Patterns for Polycystic Ovarian Syndrome, 2017-2024 20
Figure 3: Women’s Health Drugs Market, 7MM, Epidemiology Patterns for Infertility, 2017-2024 22
Figure 4: Women’s Health Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 33
Figure 5: Women’s Health Drugs Market, Global, Annual Revenue for Premarin ($bn), 2006-2024 35
Figure 6: Women’s Health Drugs Market, Global, Annual Revenue for Lupron ($bn), 2006-2024 36
Figure 7: Women’s Health Drugs Market, Global, Annual Revenue for Gonal-F ($m), 2017-2024 38
Figure 8: Women’s Health Market, Global, Annual Revenue for Mirena ($bn), 2006-2024 39
Figure 9: Women’s Health Drugs Market, Global, Annual Revenue for Celebrex ($bn), 2006-2024 40
Figure 10: Women’s Health Drugs Market, Global, Annual Revenue for Implanon/Nexplanon ($m), 2007-2024 41
Figure 11: Women’s Health Drugs Market, Global, Annual Revenue for Yasmin/Yaz ($bn), 2006-2024 43
Figure 12: Women’s Health Drugs Market, Global, Annual Revenue for Nuvaring ($m), 2006-2024 44
Figure 13: Women’s Health Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2017-2023 46
Figure 14: Women’s Health Drugs Market, Global, Annual Revenue for Esmya ($bn), 2013-2024 47
Figure 15: Women’s Health Drugs Market, Global, Annual Revenue for Orilissa ($bn), 2018-2024 49
Figure 16: Women’s Health Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 50
Figure 17: Women’s Health Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2018 51
Figure 18: Women’s Health Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018 52
Figure 19: Women’s Health Market, Global, Pipeline for Key Indications by Molecule Type, 2018 53
Figure 20: Women’s Health Drugs Market, Global, Pipeline by Molecular Target, 2018 55
Figure 21: Women’s Health Drugs Market, Global, Pipeline for Key Indications by Molecular Target Class, 2018 56
Figure 22: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development (%), 2006-2018 57
Figure 23: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006-2018 58
Figure 24: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecule Type (%), 2006-2018 59
Figure 25: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecular Target Class (%), 2006-2018 60
Figure 26: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018 61
Figure 27: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2018 62
Figure 28: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2018 63
Figure 29: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target Class (months), 2006-2018 64
Figure 30: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018 65
Figure 31: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2018 66
Figure 32: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2018 67
Figure 33: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2018 68
Figure 34: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018 69
Figure 35: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2018 70
Figure 36: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2018 71
Figure 37: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2018 72
Figure 38: Women’s Health Drugs Market, Global, Revenue Forecast for Relugolix ($m), 2021-2024 73
Figure 39: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Bremelanotide ($m), 2019-2024 74
Figure 40: Women’s Health Drugs Market, Global, Revenue Forecast for SAGE-217 ($m), 2019-2024 75
Figure 41: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Fezolinetant ($m), 2021-2024 76
Figure 42: Women’s Health Drugs Market, Global, Revenue Forecast for Zulresso ($m), 2019-2024 77
Figure 43: Women’s Health Drugs Market, Global, Revenue Forecast for Bizalimogene Ralaplasmid and Mavilimogene Ralaplasmid ($m), 2021-2024 78
Figure 44: Women’s Health Drugs Market, Global, Revenue Forecast for Retosiban ($m), 2019-2024 80
Figure 45: Women’s Health Drugs Market, Global, Market Size ($bn), 2017-2024 81
Figure 46: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024 85
Figure 47: Women’s Health Market, Global, Annual Revenue Forecast for G Protein-Coupled Receptor Target Class ($bn), 2017-2024 86
Figure 48: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Nuclear Receptor Target Class ($bn), 2017-2024 87
Figure 49: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Pathogen Target Class ($bn), 2017-2024 88
Figure 50: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Ion Channels/Transporters ($bn), 2017-2024 89
Figure 51: Women’s Health Drugs Market, Global, Company Analysis Matrix, 2017-2024 90
Figure 52: Women’s Health Market, Global, Companies by CAGR and Market Share, 2017-2024 91
Figure 53: Women’s Health Drugs Market, Global, Market Share by Company (%), 2017-2024 94
Figure 54: Women’s Health Market, Global, Companies by Compound Annual Growth Rate (%), 2017-2024 95
Figure 55: Women’s Health Market, Global, Revenues by Route of Acquisition, 2017-2024 96
Figure 56: Women’s Health Drugs Market, Global, Bayer AG Annual Revenue Forecast ($bn), 2017-2024 97
Figure 57: Women’s Health Market, Global, AbbVie Inc Annual Revenue Forecast ($bn), 2017-2024 98
Figure 58: Women’s Health Market, Global, Allergan Plc Annual Revenue Forecast ($bn), 2017-2024 99
Figure 59: Women’s Health Market, Global, Merck& Co. Annual Revenue Forecast ($bn), 2017-2024 101
Figure 60: Women’s Health Market, Global, GlaxoSmithKline Annual Revenue Forecast ($m), 2016-2023 102